血清和痰液Galectin-7表达对中度哮喘患儿奥马珠单抗治疗效果的评估价值  

The value of serum and sputum Galectin-7 expression in evaluating the therapeutic effect of omalizumab in children with moderate asthma

作　　者：张秀亚[1] 黄伟[1] 刘灵[1] 陈娇 ZHANG Xiuya;HUANG Wei;LIU Ling;CHEN Jiao(Department of Pediatrics,First Hospital of Qinhuangdao,Qinhuangdao,Hebei 066000,China)

机构地区：[1]秦皇岛市第一医院儿科,河北秦皇岛066000

出　　处：《国际检验医学杂志》2025年第4期457-461,共5页International Journal of Laboratory Medicine

基　　金：2019秦皇岛市市级科技计划自筹经费项目(201902A145)。

摘　　要：目的探讨血清和痰液半乳糖凝集素-7(Galectin-7)表达对中度哮喘患儿奥马珠单抗治疗效果的评估价值。方法选取2021年1月至2023年8月该院收治的中度哮喘患儿210例为研究对象。患儿均给予奥马珠单抗治疗,并根据哮喘临床控制标准对疗效进行评定,分为有效组、无效组。检测两组患儿治疗前血清和痰液Galectin-7表达,采用多因素Logistic回归分析血清和痰液Galectin-7与奥马珠单抗治疗中度哮喘患儿疗效之间的关系,采用受试者工作特征(ROC)曲线分析血清和痰液Galectin-7评估奥马珠单抗治疗中度哮喘患儿疗效的价值。结果两组患儿被动吸烟史占比比较差异有统计学意义(P<0.05)。有效组患儿治疗前血清和痰液Galectin-7表达均低于无效组,差异有统计学意义(P<0.05)。多因素Logistic回归分析结果显示,被动吸烟史、血清Galectin-7、痰液Galectin-7表达升高是影响奥马珠单抗治疗中度哮喘患儿疗效的独立危险因素(P<0.05)。ROC曲线分析结果显示,血清Galectin-7、痰液Galectin-7及二者联合检测评估奥马珠单抗治疗中度哮喘患儿疗效的曲线下面积分别为0.791(95%CI:0.673~0.849)、0.845(95%CI:0.766~0.925)、0.910(95%CI:0.844~0.976)。结论血清Galectin-7、痰液Galectin-7联合检测对中度哮喘患儿奥马珠单抗治疗效果的评估价值较高。Objective To investigate the value of serum and sputum Galectin-7 expression in evaluating the therapeutic effect of omalizumab in children with moderate asthma.Methods A total of 210 children with moderate asthma admitted to the hospital from January 2021 to August 2023 were selected as the study objects.All the children were treated with omazumab,and the efficacy was evaluated according to the clinical control criteria of asthma,and they were divided into effective group and ineffective group.The expression of Galectin-7 in serum and sputum before treatment was detected in the two groups.Multivariate Logistic regression was used to analyze the relationship between serum and sputum Galectin-7 and the efficacy of omalizumab in the treatment of moderate asthma children.Receiver operating characteristic(ROC)curve was used to analyze the value of serum and sputum Galectin-7 in evaluating the efficacy of omalizumab in the treatment of children with moderate asthma.Results There was statistical significance in the proportion of passive smoking between the two groups(P<0.05).The expression of Galectin-7 in serum and sputum before treatment in the effective group was lower than that in the ineffective group,and the difference was statistically significant(P<0.05).Multivariate Logistic regression analysis showed that passive smoking history,serum Galectin-7 expression and sputum Galectin-7 expression were independent risk factors affecting the efficacy of omalizumab in the treatment of moderate asthma children(P<0.05).ROC curve analysis results showed that,The area under the curve of serum Galectin-7,sputum Galectin-7 and their combination to evaluate the efficacy of omalizumab in the treatment of children with moderate asthma were 0.791(95%CI:0.673-0.849),0.845(95%CI:0.766-0.925),0.910(95%CI:0.844-0.976),respectively.Conclusion The combined detection of serum Galectin-7 and sputum Galectin-7 has a higher value in evaluating the therapeutic effect of omazumab in children with moderate asthma.

关 键 词：哮喘 奥马珠单抗 半乳糖凝集素-7 

分 类 号：R562.25[医药卫生—呼吸系统]